Volume 152, Issue 1, Pages (January 2019)

Slides:

Advertisements

Similar presentations

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Advertisements

Port-site recurrence in a patient undergoing robotic hysterectomy and lymph node dissection for endometrioid adenocarcinoma of the uterus Ioannis Alagkiozidis,

Volume 144, Issue 1, Pages (January 2017)

Ductal Carcinoma In Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, M.D., Bruce.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Elizabeth A. David, MD, David T

Volume 146, Issue 2, Pages (August 2017)

Volume 148, Issue 1, Pages (January 2018)

Volume 61, Issue 5, Pages (May 2012)

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 141, Issue 1, Pages 2-9 (April 2016)

Volume 148, Issue 1, Pages (January 2018)

Volume 151, Issue 1, Pages (October 2018)

Tumors of the esophagogastric junction

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Disease-specific survival

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Nael Martini, MDa, Manjit S. Bains, MDa, Michael E

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Volume 148, Issue 1, Pages (January 2018)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

The origins of multidisciplinary cancer care

Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma Chen-Sung Lin, MD, PhD, Chih-Tao Cheng, MD, DrPH, Chao-Yu.

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 150, Issue 1, Pages (July 2018)

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 152, Issue 1, Pages (January 2019)

Volume 142, Issue 2, Pages (August 2016)

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Volume 130, Issue 3, Pages (September 2013)

Volume 151, Issue 1, Pages (October 2018)

Volume 130, Issue 1, Pages (July 2013)

Carcinoma of the esophagus: Prognostic significance of histologic type

Volume 152, Issue 1, Pages (January 2019)

Characteristics of primary peritoneal serous carcinoma in a U. S

Volume 152, Issue 1, Pages (January 2019)

Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes.

Volume 152, Issue 1, Pages (January 2019)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Volume 115, Issue 1, Pages (October 2009)

Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas.

Nael Martini, MDa, Valerie W. Rusch, MDa, Manjit S. Bains, MDa, Mark G

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 152, Issue 1, Pages 38-45 (January 2019) Risk-based stratification of carcinomas concurrently involving the endometrium and ovary Gulisa Turashvili, Natalia R. Gómez-Hidalgo, Jessica Flynn, Mithat Gonen, Mario M. Leitao, Robert A. Soslow, Rajmohan Murali Gynecologic Oncology Volume 152, Issue 1, Pages 38-45 (January 2019) DOI: 10.1016/j.ygyno.2018.10.033 Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 1 PFS analysis by lymph node status (a) and histology of endometrial carcinoma (b) in the whole cohort (Log Rank p = 0.019 and p < 0.001) (PFS, progression-free survival). Gynecologic Oncology 2019 152, 38-45DOI: (10.1016/j.ygyno.2018.10.033) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 2 PFS analysis by lymph node status (a) and depth of myometrial invasion (b) in women with ENEC (Log Rank p = 0.003 and p < 0.001, respectively) (ENEC, endometrial non-endometrioid carcinoma; PFS, progression-free survival). Gynecologic Oncology 2019 152, 38-45DOI: (10.1016/j.ygyno.2018.10.033) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 3 a) PFS by low- and high-risk groups (Log Rank p < 0.001); b) DSS by low- and high-risk groups (Log Rank p = 0.005); c) PFS based on the original pathologists` classification of endometrial tumors as IPTs or IIIA-EC (Log Rank p = 0.07); d) DSS based on the original pathologists` classification of endometrial tumors as IPTs or IIIA-EC (Log Rank p = 0.15). (EEC, endometrial endometrioid carcinoma; ENEC, endometrial non-endometrioid carcinoma; IPTs, independent primary tumors; DSS, disease-specific survival; PFS, progression-free survival, IIIA-EC, stage IIIA endometrial carcinoma). Gynecologic Oncology 2019 152, 38-45DOI: (10.1016/j.ygyno.2018.10.033) Copyright © 2018 Elsevier Inc. Terms and Conditions

Fig. 4 A schematic diagram to illustrate risk-based stratification of carcinomas concurrently involving the endometrium and ovary (histotype refers to endometrial carcinomas; DMI, depth of myometrial invasion; LN+, lymph node positive). Gynecologic Oncology 2019 152, 38-45DOI: (10.1016/j.ygyno.2018.10.033) Copyright © 2018 Elsevier Inc. Terms and Conditions

Supplementary Fig. 1 Multivariate analysis of all EECs and ENECs subdivided based on LNS and DMI (DMI, depth of myometrial invasion; EEC, endometrial endometrioid carcinomas; ENEC, endometrial non-endometrioid carcinoma; LNS, lymph node status). Gynecologic Oncology 2019 152, 38-45DOI: (10.1016/j.ygyno.2018.10.033) Copyright © 2018 Elsevier Inc. Terms and Conditions